No abstract available.
Erythroblastosis, Fetal* ; Infant, Newborn

No abstract available.
Erythroblastosis, Fetal* ; Infant, Newborn

No abstract available.
Erythroblastosis, Fetal* ; Infant, Newborn

No abstract available.
Erythroblastosis, Fetal* ; Humans ; Infant, Newborn ; Siblings*

No abstract available.
Erythroblastosis, Fetal* ; Gene Frequency* ; Infant, Newborn

No abstract available.
Erythroblastosis, Fetal* ; Humans ; Immunoglobulin G* ; Infant, Newborn ; Infant, Newborn* ; Mothers*

ABO Blood-Group System ; Erythroblastosis, Fetal ; epidemiology ; Humans ; Infant, Newborn

Hemolytic disease of the newborn (HDN) caused by anti-M is rare and clinical manifestations are variable ranging from mild anemia and hyperbilirubinemia to hydrops fetalis and intrauterine fetal death. There were few reports of HDN caused by anti-M in Korea but no case in siblings. We experienced a case of 2 male siblings, both of whom had anti-M induced HDN and prolonged anemia persisted for over a month. We report this case with a brief review of literature. This report documents the first case of HDN caused by anti-M in siblings in Korea.
Anemia ; Erythroblastosis, Fetal ; Fetal Death ; Humans ; Hydrops Fetalis ; Hyperbilirubinemia ; Infant, Newborn* ; Jaundice ; Korea ; Male* ; Siblings*

Fetal erythroblastosis caused by maternal Rhesus alloimmunization brings a significant clinical problem, eventually leading to fetal hydrops and intrauterine fetal death. Repeated blood transfusions into the umbilical vein are the treatment of choice for fetal erythroblastosis with severe hydrops. The purpose of this report is to introduce our experience with a case of fetal erythroblastosis, recovered after intraumbilical venous transfusions. The fetus has been received the intraumbilical venous transfusions for four times from 29 weeks of gestation. Fetal hydrops and cardiomegaly, as well as polyhydramnios were improved markedly after transfusions. A healthy baby was delivered at 34 weeks of gestation. Intraumbilical venous transfusion may be a safe and effective treatment on the case with severe aggressive anemic and hydropic isoimmune fetus.
Blood Transfusion ; Cardiomegaly ; Edema ; Erythroblastosis, Fetal* ; Fetal Death ; Fetal Therapies ; Fetus ; Hydrops Fetalis ; Infant, Newborn ; Polyhydramnios ; Pregnancy ; Umbilical Veins

BACKGROUND: Several studies on the frequency and distribution of unexpected antibodies of Koreans have been done by some investgators. But more studies are necessory to grasp the real frequency and distribution. We hoped to investigate the frequency and distribution of unexpected antiboddis of Koreans. METHODS: We performed 188 unexpected antibody identification tests to evaluate the distribution of unexpected antibodies from May 1997 to June 1998. The sera we tested are antibody screening positive ones sent from 11 hospitals and 1 blood center. We also analized the frequecny of unexpected antibodues from the data of Dongsan Medical Center's antibody screening tests. RESULTS: The frequency of unexpected antibody of this study (using tube method) was 1.0%. Both anti-Lea and anti-E (with anti-c) antibodies were the most frequent antibodies up to 31 cases (33.0%) each. Among the identified antibodies from Dongsan Medical Center which used tube method, anti-Lea antibody was the most frequent antibody (41.3%). Otherwise among the identified antibodies from other two hospitals which used gel card method, anti-E (with anti-c) antibody was the most frequent antibody (45.5%). The cause of all four cases of hemolytic disease of newborn was anti-E antibody. About half of the specimens' antibodies were not identified due to the problemes of identification cells, tested sera, test methods. CONCLUSION: Anti-Lea and anti-E (with anti-c) antibodies were the most frequent ones in Korean people. But the prequency was varied according to antibody screenig test methods. Anti-E antibody is the most important unexpected antibidy for hemolytic disease of newborn in Korea. To decrease the missed cases of antibody identification tests both Korean and foreign identification cells, enzyme method should be used.
Antibodies* ; Erythroblastosis, Fetal ; Hand Strength ; Hope ; Infant, Newborn ; Korea ; Mass Screening